The information on this page is updated via a feed from the London Stock Exchange's Regulatory News Service.
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
Report of Foreign
Issuer
Pursuant to Rule
13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For
June 2008
Commission File
Number: 001-11960
AstraZeneca
PLC
15 Stanhope Gate,
London W1K 1LN, England
Indicate by check
mark whether the registrant files or will file annual reports under cover of
Form 20-F or Form 40-F.
Form 20-F X
Form
40-F ___
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1):
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): ______
Indicate by check
mark whether the registrant by furnishing the information contained in this Form
is also thereby furnishing the information to the Commission pursuant to Rule
12g3-2(b) under the Securities Exchange Act of 1934.
Yes __ No X
If
“Yes” is marked, indicate below the file number assigned to the Registrant in
connection with Rule 12g3-2(b): 82-_____________
AstraZeneca
PLC
INDEX TO
EXHIBITS
1.
Press release
entitled, “AstraZeneca Submits an sNDA for SYMBICORTÒ
for the Treatment of Asthma in Children as Young as Age Six”, dated 4 June
2008.
2.
Press release
entitled, “Repurchase of shares in AstraZeneca PLC”, dated 5 June
2008.
3.
Press release
entitled, “Repurchase of shares in AstraZeneca PLC”, dated 10 June
2008.
4.
Press release
entitled, “Repurchase of shares in AstraZeneca PLC”, dated 11 June
2008.
5.
Press release
entitled, “Repurchase of shares in AstraZeneca PLC”, dated 12 June
2008.
6.
Press release
entitled, “Repurchase of shares in AstraZeneca PLC”, dated 13 June
2008.
7.
Press release
entitled, “Repurchase of shares in AstraZeneca PLC”, dated 16 June
2008.
8.
Press release
entitled, “Repurchase of shares in AstraZeneca PLC”, dated 18 June
2008.
9.
Press release
entitled, “Repurchase of shares in AstraZeneca PLC”, dated 19 June
2008.
10.
Press release
entitled, “Repurchase of shares in AstraZeneca PLC”, dated 23 June
2008.
11.
Press release
entitled, “Repurchase of shares in AstraZeneca PLC”, dated 26 June
2008.
12.
Press release
entitled, “Repurchase of shares in AstraZeneca PLC”, dated 27 June
2008.
13.
Press release
entitled, “Transparency Directive Voting Rights and Capital”, dated 30
June 2008.
14.
Press release
entitled, “AstraZeneca launches and prices a EUR 500 million Eurobond”,
dated 30 June 2008.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
AstraZeneca
PLC
Date: 08 July
2008
By:
/s/
Justin Hoskins
Name: Justin Hoskins
Title: Deputy
Company Secretary
Item
1
AstraZeneca Submits an sNDA for
SYMBICORT® for the
Treatment of Asthma in
Children as Young as Age Six
AstraZeneca today announced that it
submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug
Administration (FDA) for approval of a new indication for
SYMBICORT® (budesonide/formoterol fumarate
dihydrate) Inhalation
Aerosol for the long-term
maintenance treatment of asthma in paediatric patients ages 6 to 11 years
old. SYMBICORT is currently approved for the
long-term maintenance
treatment of asthma in patients 12 years and older.
“Millions of children in the U.S.
are affected by asthma,” said lead investigator Jeffrey
Leflein, MD, Allergy & Immunology Associates of Ann Arbor, Michigan. “SYMBICORT could potentially offer
another treatment option
for the long-term maintenance of asthma in young children whose condition
is not adequately controlled with inhaled corticosteroids alone.”
The submission package is based on a
robust clinical development program consisting of five active or placebo-controlled Phase III
trials assessing the efficacy and safety of SYMBICORT pressurized
metered-dose inhaler (pMDI) that
included 1,446 children ages 6 to 11 years old with asthma. The proposed
starting dose for children (80/9 mcg twice-daily) was studied in one pivotal
randomized, double-blind, active-controlled, 12-week study that evaluated
256 children ages 6 to 11 years old with mild-to-moderate persistent asthma previously
treated with inhaled corticosteroid therapy. In this study, SYMBICORT was
compared to budesonide pMDI and formoterol dry powder inhaler. A second study
evaluating this dose included 351 subjects ages 6 to 11 years old. Results from
both studies demonstrated that SYMBICORT 80/9 mcg twice daily had a similar
safety profile to one of the mono-components, budesonide; likewise, results from
the first study also found that SYMBICORT 80/9 mcg twice daily had a similar
safety profile to its other mono-component, formoterol. The most common adverse
events reported were headache, pyrexia, upper respiratory tract infection,
nasopharyngitis, and pharyngolaryngeal pain.
About
Paediatric Asthma
Asthma is a chronic disease of the
lungs that affects children, as well as adults, and it can be life threatening
if not properly managed. Nearly 9 million children in the U.S
have been diagnosed with asthma at some point in their lives. Asthma is a
cause of school absenteeism, accounting for nearly 13 million missed days of
school in 2003. It is also the second leading respiratory disease to cause
hospitalization in children under the age of 15. According to the National
Institutes of Health Guidelines, combination therapy is recommended for children
with severe persistent asthma or in those not adequately controlled with medium
doses of inhaled corticosteroids alone. The annual direct healthcare cost of the
disease for children and adults in the U.S. is approximately $14.7 billion.
Indirect costs (e.g., lost productivity due to missed days at school or work)
add another $5 billion, for a total cost of $19.7 billion.
About
SYMBICORT
SYMBICORT is a combination therapy
indicated for the long-term maintenance treatment of asthma in patients 12 years
of age and older. Administered twice daily, SYMBICORT is a combination of two
proven asthma medications
– budesonide, an inhaled corticosteroid
(ICS), and formoterol, a rapid and long-acting beta2-agonist (LABA). SYMBICORT does not
replace fast-acting inhalers and should not be used to treat acute symptoms of
asthma.
About
AstraZeneca
AstraZeneca is a major international healthcare business
engaged in the research, development, manufacturing and marketing of meaningful
prescription medicines and supplier for healthcare services. AstraZeneca is one
of the world's leading pharmaceutical companies with healthcare sales of $29.55 billion and is
a leader in gastrointestinal, cardiovascular, neuroscience, respiratory,
oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.35 billion dollar
healthcare business with 12,200 employees committed to improving
people’s lives. AstraZeneca is listed in the
Dow Jones Sustainability Index (Global) as well as the FTSE4Good
Index.
For more information
visit www.astrazeneca.com.
4 June 2008
Media Enquiries:
Steve Brown +44 207 304 5033 (24
hours)
Chris Sampson +44 20 7304 5130 (24
hours)
Neil McCrae +44 207 304 5045 (24
hours)
Investor Enquiries UK:
Jonathan Hunt +44 207 304 5087 mob: +44
7775 704032
Mina Blair +44 20 7304 5084 mob: +44
7718 581021
Karl Hard +44 207 304 5322 mob: +44 7789
65436
Investor Enquiries US:
Ed Seage +1 302 886 4065 mob: +1 302 373
1361
Jorgen Winroth +1 212 579 0506 mob: +1
917 612 4043
Peter Vozzo (MedImmune) +1 301 398 4358
mob: +1 301 252 7518
- Ends -
Item 2
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
AstraZeneca PLC
announced that on 4 June 2008, it purchased for cancellation 325,000 ordinary
shares of AstraZeneca PLC at a price of 2177 pence per share. Upon the
cancellation of these shares, the number of shares in issue will be
1,455,889,565.
G H R
Musker
Company
Secretary
5 June
2008
Item 3
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
AstraZeneca PLC
announced that on 9 June 2008, it purchased for cancellation 750,000 ordinary
shares of AstraZeneca PLC at a price of 2150 pence per share. Upon the
cancellation of these shares, the number of shares in issue will be
1,455,142,522.
G H R
Musker
Company
Secretary
10 June
2008
Item 4
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
AstraZeneca PLC
announced that on 10 June 2008, it purchased for cancellation 450,000 ordinary
shares of AstraZeneca PLC at a price of 2117 pence per share. Upon the
cancellation of these shares, the number of shares in issue will be
1,454,692,522.
G H R
Musker
Company
Secretary
11 June
2008
Item 5
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
AstraZeneca PLC
announced that on 11 June 2008, it purchased for cancellation 225,000 ordinary
shares of AstraZeneca PLC at a price of 2086 pence per share. Upon the
cancellation of these shares, the number of shares in issue will be
1,454,467,522.
G H R
Musker
Company
Secretary
12 June
2008
Item 6
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
AstraZeneca PLC
announced that on 12 June 2008, it purchased for cancellation 300,000 ordinary
shares of AstraZeneca PLC at a price of 2089 pence per share. Upon the
cancellation of these shares, the number of shares in issue will be
1,454,167,522.
G H R
Musker
Company
Secretary
13 June
2008
Item 7
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
AstraZeneca PLC
announced that on 13 June 2008, it purchased for cancellation 500,000 ordinary
shares of AstraZeneca PLC at a price of 2094 pence per share. Upon the
cancellation of these shares, the number of shares in issue will be
1,453,667,522.
G H R
Musker
Company
Secretary
16 June
2008
Item 8
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
AstraZeneca PLC
announced that on 17 June 2008, it purchased for cancellation 400,000 ordinary
shares of AstraZeneca PLC at a price of 2098 pence per share. Upon the
cancellation of these shares, the number of shares in issue will be
1,453,921,168.
G H R
Musker
Company
Secretary
18 June
2008
Item 9
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
AstraZeneca PLC
announced that on 18 June 2008, it purchased for cancellation 300,000 ordinary
shares of AstraZeneca PLC at a price of 2085 pence per share. Upon the
cancellation of these shares, the number of shares in issue will be
1,453,621,168.
G H R
Musker
Company
Secretary
19 June
2008
Item 10
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
AstraZeneca PLC
announced that on 20 June 2008, it purchased for cancellation 230,000 ordinary
shares of AstraZeneca PLC at a price of 2096 pence per share. Upon the
cancellation of these shares, the number of shares in issue will be
1,453,393,720.
G H R
Musker
Company
Secretary
23 June
2008
Item 11
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
AstraZeneca PLC
announced that on 25 June 2008, it purchased for cancellation 300,000 ordinary
shares of AstraZeneca PLC at a price of 2158 pence per share. Upon the
cancellation of these shares, the number of shares in issue will be
1,453,103,660.
G H R
Musker
Company
Secretary
26 June
2008
Item 12
REPURCHASE
OF SHARES IN ASTRAZENECA PLC
AstraZeneca PLC
announced that on 26 June 2008, it purchased for cancellation 200,000 ordinary
shares of AstraZeneca PLC at a price of 2156 pence per share. Upon the
cancellation of these shares, the number of shares in issue will be
1,452,903,660.
G H R
Musker
Company
Secretary
27 June
2008
Item 13
Transparency
Directive
Voting
Rights and Capital
The following
notification is made in accordance with the UK Financial Services Authority
Disclosure and Transparency Rule 5.6.1. On 30 June 2008 the
issued share capital of AstraZeneca PLC with voting rights is 1,452,916,003
ordinary shares of US$0.25. No shares are held in Treasury.
Therefore, the total number of voting rights in AstraZeneca PLC is
1,452,916,003.
The above figure for
the total number of voting rights may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to notify
their interest in, or a change to their interest in, AstraZeneca PLC under the
FSA's Disclosure and Transparency Rules.
G
H R Musker
Company
Secretary
30
June 2008
Item 14
Not
for release, publication or distribution directly or indirectly in or into the
United States, Canada, Australia or Japan
AstraZeneca
launches and prices a EUR 500 million eurobond
AstraZeneca PLC,
rated A1 (stable) by Moody's and AA- (stable) by Standard & Poor's,
announces the successful pricing of a EUR 500 million eurobond transaction (the
“Bond”). The proceeds of the issue will be used to repay a portion of
the outstanding US commercial paper taken on in connection with the acquisition
of MedImmune.
The bond is a EUR
500 million, fixed rate issue with a coupon of 5.625 per cent maturing 4th
January 2010 and was issued under AstraZeneca PLC’s Euro Medium Term Note (EMTN)
programme.
The Bonds will be
issued to institutional investors outside the US in accordance with Regulation S
of the U.S. Securities Act of 1933, as amended. The Bonds will be
admitted to listing on the UKLA's Official List and to trading on the regulated
market of the London Stock Exchange.
30
June 2008
Media
Enquiries:
Steve
Brown
+44 207 304
5033 (24 hours)
Chris
Sampson
+44 20 7304
5130 (24 hours)
Neil
McCrae
+44 207 304
5045 (24 hours)
Investor
Enquiries UK:
Jonathan
Hunt
+44 207 304
5087
mob: +44 7775
704032
Mina
Blair
+44 20 7304
5084
mob: +44 7718
581021
Karl
Hard
+44 207 304
5322
mob: +44 7789
654364
Investor
Enquiries US:
Ed
Seage
+1 302 886
4065
mob: +1 302
373 1361
Jorgen
Winroth
+1 212 579
0506
mob: +1 917
612 4043
Peter Vozzo
(MedImmune)
+1 301 398
4358
mob: +1 301
252 7518
About
AstraZeneca
AstraZeneca is a
major international healthcare business engaged in research, development,
manufacturing and marketing of prescription pharmaceuticals and supplier for
healthcare services. AstraZeneca is one of the world's leading pharmaceutical
companies with healthcare sales of US $29.55 billion and is a leader in
gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and
infection product sales. AstraZeneca is listed in the Dow Jones Sustainability
Index (Global) as well as the FTSE4Good Index. For more Information visit www.astrazeneca.com
About
the announcement
This announcement is
for information only and does not constitute an offer or invitation to subscribe
for or purchase any securities.
The securities have
not been, nor will they be, registered under the U.S. Securities Act of 1933, as
amended (the "Securities Act"), and no securities shall be offered or sold in
the United States or to U.S. persons (as those terms are defined in Regulation S
under the Securities Act) absent registration or an applicable exemption from
the registration requirements of the Securities Act. There will be no
public offering of the securities in the United States in connection with this
transaction.
-
Ends -
